3435-29-8Relevant articles and documents
Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity
Chen, Yadong,Dong, Ruinan,Duan, Chunqi,Huang, Jianhang,Jiang, Fei,Li, Hongmei,Li, Shuwen,Liu, Chenhe,Lu, Tao,Tang, Weifang,Wang, Xinren,Xu, Junyu,Zhang, Tianyi,Zhang, Yanmin,Zhu, Gaoyuan,Zhu, Yuqin
, (2020/05/22)
Specific inhibition of CDK9 is considered a promising strategy for developing effective anticancer therapeutics. However, most of the reported CDK9 inhibitors are still at an early stage of development and lack selectivity against other CDKs. Herein, we discovered coumarin derivative 30i as a potent CDK9 inhibitor with high selectivity (8300-fold over CDK7). Binding mode analysis illustrated that the substituent coumarin moiety is a critical group for CDK9 selectivity by occupying a flexible hinge/αD region, which is sterically hindered in other CDKs. Compound 30i showed excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. Moreover, 30i significantly induced tumour growth inhibition in a dose-dependent manner without causing an obvious loss of body weight in an MV4-11 xenograft mice model. Altogether, these results suggest that 30i may serve as a potential acute myeloid leukaemia (AML) therapeutics by selectively targeting CDK9.
Design and synthesis of a novel series of 4-heteroarylamino-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octanes as α7 nicotinic receptor agonists 2. Development of 4-heteroaryl SAR
Iwuagwu, Christiana,King, Dalton,McDonald, Ivar M.,Cook, James,Zusi, F. Christopher,Hill, Matthew D.,Mate, Robert A.,Fang, Haiquan,Knox, Ronald,Gallagher, Lizbeth,Post-Munson Amy Easton, Debra,Miller, Regina,Benitex, Yulia,Siuciak, Judy,Lodge, Nicholas,Zaczek, Robert,Morgan, Daniel,Bristow, Linda,Macor, John E.,Olson, Richard E.
supporting information, p. 1261 - 1266 (2017/06/19)
Quinuclidine-containing spirooxazolines, as described in the previous report in this series, were demonstrated to have utility as α7 nicotinic acetylcholine receptor (α7 nAChR) partial agonists. In this work, the SAR of this chemotype was expanded to include an array of diazine heterocyclic substitutions. Many of the heterocyclic analogs were potent partial agonists of the α7 receptor, selective against other nicotinic receptors and the serotinergic 5HT3A receptor. (1′S,3′R,4′S)-N-(6-phenylpyrimidin-4-yl)-4H-1′-azaspiro[oxazole-5,3′-bicyclo[2.2.2]octan]-2-amine, a potent and selective α7 nAChR partial agonist, was demonstrated to improve cognition in the mouse novel object recognition (NOR) model of episodic memory.
QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
-
Page/Page column 152, (2011/05/11)
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.